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Discovery of cancer common and specific driver
gene sets
Junhua Zhang and Shihua Zhang
Abstract—Cancer is known as a disease mainly caused by gene alterations. Discovery of mutated driver pathways or gene sets is
becoming an important step to understand molecular mechanisms of carcinogenesis. However, systematically investigating
commonalities and specificities of driver gene sets among multiple cancer types is still a great challenge, but this investigation will
undoubtedly benefit deciphering cancers and will be helpful for personalized therapy and precision medicine in cancer treatment. In
this study, we propose two optimization models to de novo discover common driver gene sets among multiple cancer types (ComMDP)
and specific driver gene sets of one certain or multiple cancer types to other cancers (SpeMDP), respectively. We first apply ComMDP
and SpeMDP to simulated data to validate their efficiency. Then, we further apply these methods to 12 cancer types from The Cancer
Genome Atlas (TCGA) and obtain several biologically meaningful driver pathways. As examples, we construct a common cancer
pathway model for BRCA and OV, infer a complex driver pathway model for BRCA carcinogenesis based on common driver gene sets
of BRCA with eight cancer types, and investigate specific driver pathways of the liquid cancer lymphoblastic acute myeloid leukemia
(LAML) versus other solid cancer types. In these processes more candidate cancer genes are also found.
Index Terms—Bioinformatics, cancer genomics, pan-cancer study, driver pathway, mutual exclusivity
✦
1 INTRODUCTION
CANCER is a complex and heterogeneous disease withdiverse genetic and environmental factors involved in
its etiology. With the advances of deep sequencing technol-
ogy, huge volume cancer genomics data have been gener-
ated through several large-scale programs (e.g., The Cancer
Genome Atlas (TCGA) [1], International Cancer Genome
Consortium (ICGC) [2], and the Cancer Cell Line Encyclo-
pedia (CCLE) [3]), which provide huge opportunities for
understanding the molecular mechanisms and pathogenesis
underlying cancer [4]. Currently, a crucial challenge in can-
cer genomics is to distinguish driver mutations and driver
genes which contribute to cancer initiation and develop-
ment from passenger ones which accumulate in cells but do
not contribute to carcinogenesis [5], [6]. Most early efforts
have been devoted to detect individual driver genes with
recurrent mutations [7]. However, this kind of methods do
not consider the complicated mutational heterogeneity in
cancer genomes with diverse mutations in genes.
Although cancer patients exhibit diverse genomic alter-
ations, many studies have demonstrated that driver muta-
tions tend to affect a limited number of cellular signaling
and regulatory pathways [1], [8], [9]. Therefore, a great deal
of attention has been devoted to evaluate the recurrence of
mutations in groups of genes derived from known path-
ways or protein-protein interaction networks [9], [10], [11].
These groups of genes are considered as candidate driver
pathways, which may be frequently perturbed within tumor
cells [12], [13] and can lead to the acquisition of carcino-
genic properties such as cell proliferation, angiogenesis, or
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metastasis [14], [15]. A main concern is that the human
protein interaction network and biological pathways are
far from being complete. It is necessary to develop new
methods without relying on prior knowledge to discover
novel mutated driver gene sets or pathways.
Previous studies indicate that a driver gene set has two
key properties: (1) covering a large number of samples
(high coverage); and (2) its mutations tend to exhibit mutual
exclusivity (high mutual exclusivity), i.e., a single mutation
is usually enough to disturb one pathway [8], [16], [17].
For example, the mutation of TP53 and the copy number
amplification of MDM2 seldom appear simultaneously in
glioblastoma multiforme (GBM) patients (p53 pathway) [1].
These rules have been frequently used to de novo discover
mutated driver gene sets in recent years [18], [19], [20]. For
example, Vandin et al. developed Dendrix by designing a
weight function to combine the coverage and exclusivity of a
gene set, and maximizing it via a Markov chain Monte Carlo
(MCMC) approach to extract driver gene sets [18]. Zhao et
al. further developed a binary linear programming (BLP)
model [19] to get the exact solutions of the maximization
problem, and designed a genetic algorithm to optimize
variant weight functions and incorporate prior biological
knowledge into it in a more flexible manner. However, these
studies have all focused on a single pathway without con-
sidering the cooperativeness between pathways [18], [19],
[20], [21].
In fact, a great deal of evidence has suggested that
pathways often function cooperatively in cancer initiation
and progression [15], [16], [22], [23]. Thus, exploring the
complex collaboration among different biological pathways
and functional modules may shed new lights on the un-
derstanding of the cellular mechanisms underlying carcino-
genesis. Leiserson et al. [24] generalized Dendrix (Multi-
Dendrix) to simultaneously identify multiple driver gene
2sets in cancer. More importantly, the collaboration among
different pathways means these gene sets are likely simul-
taneously mutated in a large cohort of patients. To this end,
Zhang et al. [25] developed CoMDP to de novo discover co-
occurring mutated driver gene sets in cancer by introducing
a novel weight function and a mathematical programming
model; Melamed et al. [26] introduced an information theo-
retic method GAMToC to identify combinations of genomic
alterations in cancer; and Remy et al. [27] developed a log-
ical model to explain mutually exclusive and co-occurring
genetic alterations in bladder carcinogenesis.
On the other hand, different cancer types may have
certain commonalities [28]. Investigating the similarities
and differences among multiple cancer types may enhance
the understanding of pathologies underlying cancers and
provide new clues to efficient drug design and cancer
treatment. The TCGA pan-cancer project surveyed multi-
platform aberration data in cancer samples from thou-
sands of cancer patients among 12 cancer types [29], which
provides huge opportunities to make such investigations
[30], [31]. For example, different histological cancers can
be classified into the same clusters [30], [32], [33], which
means that different cancers may be treated by the same
drugs. Recently, Leiserson et al. [34] proposed a directed heat
diffusion model (HotNet2) to identify pathways and protein
complexes based on pan-cancer network analysis; Kim et
al. [35] investigated different kinds of mutual exclusivity
among multiple cancer types and designed statistical testing
methods for driver gene set identification (MEMCover). Al-
though recent pan-cancer studies revealed that some pairs of
genes showing mutually exclusivity are common or specific
for some cancer types [28], [36], there is still a lack of
systematic investigation of commonalities and specificity in
pathway level.
In this study, we develop two mathematical program-
ming models (ComMDP and SpeMDP) to de novo identify
cancer common and specific driver gene sets, respectively.
For the former, we detect a set of genes which have sig-
nificantly high mutual exclusivity and large coverage in
two or more cancer types simultaneously. For the latter, we
identify a driver gene set specific to one or a group of cancer
types (say, S1) versus another group of cancer types (say,
S2). In other words, we require the detected genes to have
significantly high mutual exclusivity and large coverage in
the group S1 but not in S2. We first apply ComMDP and
SpeMDP to simulated data to validate their effectiveness.
Then, we apply them to the mutation data of 12 cancer types
from the pan-cancer project [29], [30] and obtain several
biologically meaningful driver gene sets. For example, for
breast carcinoma (BRCA) and ovarian carcinoma (OV), we
identify their common driver gene sets as well as their
individual specific driver gene sets relative to the other.
Interestingly, the identified common gene sets are involved
with distinct cancer pathways such as apoptosis pathway,
ErbB signaling pathway, PI3K-Akt signaling pathway and
MAPK signaling pathway, which enable us to construct a
common cancer pathway model for BRCA and OV. Fur-
ther, we construct a hypothetical mutated driver pathway
model for BRCA carcinogenesis and progression based on
eight common driver gene sets of BRCA with eight cancer
types, indicating the complexity of BRCA carcinogenesis.
gene
somatic mutation
copy number alteration
genomes
s
a
m
p
le
gene
DNA methylation aberration
A
B
C
Common 
driver gene set 
of A, B and C
Specific driver 
gene set of A 
versus B and C
a
b = mutated
= not mutated
Fig. 1. Schematic illustration of the key idea of this study. (a) Obtain
the mutation matrix from the sequencing data (referring to somatic
mutations, copy number alterations (CNAs) and DNA methylation aber-
rations) [18]. (b) Identify the common and specific driver gene sets using
ComMDP and SpeMDP.
In addition, we investigate specific driver pathways of
the liquid cancer lymphoblastic acute myeloid leukemia
(LAML) versus other solid cancer types, and identify mu-
tations of FLT3, IDH2, NRAS, IDH1, RUNX1, NPM1, TET2,
KIT, amplifications of MLL, IGSF5, and deletions of TP53,
GNAQ, which are involved in proliferation, transcriptional
deregulation, impaired hematopoietic differentiation, and
so on. We expect the proposed methods can discover new
commonalities and specificities among cancers and help to
understand cancer initialization and progression further.
2 MATERIALS AND METHODS
We first briefly describe the maximum weight submatrix
problem, where the coverage and exclusivity of a gene set is
combined to form a weight function for discovering driver
gene sets in a single mutation data [18], [19]. Then we
propose ComMDP and SpeMDP to de novo discover can-
cer common and specific mutated driver gene sets among
multiple cancer types, respectively (Fig. 1).
32.1 The maximum weight submatrix problem
Given a binary mutation matrix A with m rows (samples)
and n columns (genes), Vandin et al. introduced a weight
function W and defined the maximum weight submatrix
problem [18]. Specifically, it is designed to find a submatrix
M of sizem× k in matrix A by maximizingW :
W (M) = |Γ(M)| − ω(M) = 2|Γ(M)| −
∑
g∈M
|Γ(g)|, (1)
where Γ(g) = {i : Aig = 1} denotes the set of samples in
which the gene g is mutated, Γ(M) = ∪g∈MΓ(g) measures
the coverage of M , and ω(M) =
∑
g∈M |Γ(g)| − |Γ(M)|
measures the coverage overlap ofM .
2.2 ComMDP for identifying common mutated driver
gene sets among two or multiple cancer types
Considering R (R ≥ 2) cancer types, for each we have the
mutation matrix Ar = (a
(r)
ij ) withmr samples and the same
nmutated genes (r = 1, . . . , R). To find a common mutated
driver gene setM with large coverage and high exclusivity,
we introduce a weight function Cm:
Cm(M) =
R∑
r=1
[
2|ΓAr(M)| −
∑
g∈M
|ΓAr (g)|
]
. (2)
We propose the following BLP model to maximize it:
max Fm(x, u) =
R∑
r=1
[
2
mr∑
i=1
x
(r)
i −
n∑
j=1
(
uj ·
mr∑
i=1
a
(r)
ij
)]
(3)
s.t.


x
(r)
i ≤
n∑
j=1
a
(r)
ij uj, i = 1, . . . ,mr, r = 1, . . . , R,
n∑
j=1
uj = K,
x
(r)
i , uj ∈ {0, 1}, i = 1, . . . ,mr, j = 1, . . . , n,
r = 1, . . . , R,
(4)
where uj indicates whether column j of the mutation ma-
trices falls into submatrx M or not, and all the columns j’s
with uj = 1 constitute M ; x = {x
(1), . . . , x(R)}, and x
(r)
i
indicates whether the entries of row i are zeros or not in
Ar (r = 1, . . . , R). Thus,
∑mr
i=1 x
(r)
i represents the coverage
of M in Ar (i.e., |ΓAr(M)|); K is the total number of genes
withinM .
2.3 SpeMDP for identifying a certain or multiple cancer
specific driver gene sets
Suppose we want to find the specific mutated driver gene
sets for R cancer types relative to other T ones (R ≥ 1, T ≥
1). We use Ar = (a
(r)
ij ) (r = 1, . . . , R) and Bt = (b
(t)
kj )
(t = 1, . . . , T ) to denote corresponding mutation matrices,
respectively. We introduce the weight function Sm:
Sm(M) =
1
R
R∑
r=1
[
K|ΓAr(M)| −
∑
g∈M
|ΓAr (g)|
]
−
1
T
T∑
t=1
[
K|ΓBt(M)| −
∑
g∈M
|ΓBt(g)|
]
.
(5)
We maximize Sm by the following BLP model:
max Gm(x, y, u) =
1
R
R∑
r=1
[
K
mr∑
i=1
x
(r)
i −
n∑
j=1
(
uj ·
mr∑
i=1
a
(r)
ij
)]
−
1
T
T∑
t=1
[
K
lt∑
k=1
y
(t)
k −
n∑
j=1
(
uj ·
lt∑
k=1
b
(t)
kj
)]
,
(6)
s.t.


x
(r)
i ≤
n∑
j=1
a
(r)
ij uj , i = 1, . . . ,mr, r = 1, . . . , R,
1
n
n∑
j=1
b
(t)
kj uj ≤ y
(t)
k ≤
n∑
j=1
b
(t)
kj uj ,
k = 1, . . . , lt, t = 1, . . . , T,
n∑
j=1
uj = K,
x
(r)
i , y
(t)
k , uj ∈ {0, 1}, i = 1, . . . ,mr, j = 1, . . . , n,
r = 1, . . . , R, k = 1, . . . , lt, t = 1, . . . , T,
(7)
where x = {x(1), . . . , x(R)}, y = {y(1), . . . , y(T )}. As stated
above, the constraint x
(r)
i ≤
∑n
j=1 a
(r)
ij uj in Eq. (7) ensures
that
∑mr
i=1 x
(r)
i is the coverage of M in Ar . In Eq. (5) or Eq.
(6), because of the subtraction of the weights of Bt from
that of Ar , we use the restrictions
1
n
∑n
j=1 b
(t)
kj uj ≤ y
(t)
k ≤∑n
j=1 b
(t)
kj uj to ensure that
∑lt
k=1 y
(t)
k is the coverage of M
in Bt, and we use the coefficient K to ensure the weights of
Ar and Bt are all non-negative.
2.4 Statistical significance
We perform a permutation test to assess the significance of
results. We permutate the mutations independently among
samples to preserve the mutation frequency of each gene.
Two kinds of significance are calculated: (1) individual
one measuring the significance of a gene set in a certain
mutation matrix, where the weight W in Eq. (1) is used as
the statistic; (2) overall one measuring the significance of a
gene set by viewing all the mutation matrices as a whole,
where the weight Cm in Eq. (2) and the weight Sm in Eq.
(5) are used as the statistics for ComMDP and SpeMDP,
respectively.
2.5 Simulated data
To assess the performance of the proposed methods on a
variety of data, we construct eight datasets, sd1, · · · , sd8,
for simulation study. For convenience of description, in the
following we use Ar or Br to denote the mutation matrices,
M
(r)
i to denote the i-th embedded submatrix (or gene set)
in Ar or Br for which the proposed methods are used to
identify, and p
(r)
i to denote the gene mutation rate in M
(r)
i
(1 ≤ r ≤ R, 1 ≤ i ≤ I).
The datasets sd1 and sd2 are generated to illustrate the
performance of ComMDP for identifying common driver
gene sets among multiple cancer types. The difference is
that in sd1 for each r the M
(r)
i have a constant mutation
rate (1 ≤ i ≤ I), but in sd2 they have varying ones, to
investigate the possible impact of mutation rates in the gene
4sets on the discovery accuracy. sd1 is constructed as follows.
First, we have three empty matrices Ar with the same sizes:
m (samples) × n (genes) (here m = 500, n = 900). Then,
we embed I submatrices M
(r)
i with a mutation rate p
(r)
into each matrix Ar (r = 1, · · · , 3; i = 1, · · · , I ; I = 9;
p(1) = 0.80, p(2) = 0.85, p(3) = 0.90), where for each r,
M
(r)
i contains i + 1 genes (i = 1, · · · , I), and for each i,
these submatrices M
(r)
i occupy the same columns in the
corresponding Ar (r = 1, · · · , 3). For each sample in Ar , a
gene uniformly chosen fromM
(r)
i is mutated with rate p
(r),
and once one gene is mutated, the other genes inM
(r)
i have
a rate p0 to be mutated (p0 = 0.04). Finally, the genes not
inM
(r)
i are mutated in at most three samples, which can be
viewed as the background mutation rate in the simulated
data. The dataset sd2 is constructed in a similar way, the
difference is that each gene set has 9 genes (K = 9), and
M
(r)
i has a mutation rate p
(r)
i = 1−i∗δ(r)(r = 1, · · · , 3; i =
1, · · · , 9), where δ(1) = 0.03, δ(2) = 0.04, δ(3) = 0.05.
The simulated datasets sd3-sd7 are generated to demon-
strate the performance of SpeMDP for identifying specific
driver gene sets of one or several cancer type(s) versus
other cancers. In this case, the datasets are constructed to
contain two kinds of embedded gene sets. The first kind
of gene sets have mutations with (approximately) mutual
exclusivity, like those in sd1 (called the first manner of
embedding); but for the second ones, we randomly select
60% samples for which two genes are randomly chosen to
be mutated with proper mutation rates, ensuring they are
not exclusive (called the second manner of embedding). For
the details of the construction of sd3-sd7, please refer to
the Supplementary Data. We use these five datasets sd3-sd7
to investigate different aspects for SpeMDP applications.
Specially,
- sd3 for discovering a certain cancer specific driver gene
sets
- sd4 for investigating in which case SpeMDP can iden-
tify specific driver gene sets
- sd5 for investigating the impact of diverse mutation
rates on the results
- sd6 for investigating the method performance in differ-
ent mutation generation manners
- sd7 for discovering multiple cancer specific driver gene
sets
We construct dataset sd8 to see if the previous individual
cancer type approaches can also identify cancer common
and specific driver gene sets (e.g., BLP in MDPFinder [19]
or Dendrix [18]). The construction of sd8 is similar to that
of sd1. Seven groups of submatrices M
(r)
i with 6 genes in
each are embedded into Ar with m = 500, n = 700, r =
1, · · · , 3. The first group of submatrices are constructed
in the first embedding manner (thus corresponding to a
common driver gene set); each of the 2nd to the 4th groups
contains two with the first embedding manner, one with
background mutations (corresponding to neither common
nor specific driver gene sets); each of the last three groups
contains one with the first embedding manner, two with
background mutations (each corresponding to a specific
driver gene set).
2.6 Biological data
We use mutation data from the pan-cancer project [30],
[33] to assess our methods for practical applications. The
12 types of cancer include bladder carcinoma (BLCA),
breast carcinoma (BRCA), colon adenocarcinoma (COAD),
glioblastoma multiformae (GBM), head and neck squa-
mous carcinoma (HNSC), kidney renal clear-cell carcinoma
(KIRC), lymphoblastic acute myeloid leukemia (LAML),
lung adenocarcinoma (LUAD), lung squamous carcinoma
(LUSC), ovarian carcinoma (OV), rectal adenocarcinoma
(READ), and uterine cervical and endometrial carcinoma
(UCEC). Here colon adenocarcinoma and rectal adenocarci-
noma are combined into one type denoted as COADREAD.
3 RESULTS
3.1 Simulation study
We first apply ComMDP to the simulated datasets sd1, sd2
and apply SpeMDP to sd3 - sd7 to assess their performance.
We run each method ten times for each dataset. We further
apply them to sd8 and compare them with driver gene set
discovery approaches for individual cancer types (BLP [19]
is used here).
3.1.1 Common driver gene set discovery.
For sd1 ComMDP can identify the embedded gene sets for
all the ten runs when the number of genes K ≤ 8 (Fig. 2a).
When K = 9, it can detect the embedded gene set for five
runs, and it has a wrong one for each of other five runs.
When K = 10, each detection of eight runs contains nine
correct genes plus a wrong one, and each of other two runs
has two wrong ones. We also investigate the possible impact
of varying mutation rates in the gene sets on the discovery
accuracy. For the embedded nine gene sets of K = 9 with
diverse mutation rates in sd2, each of ten runs can identify
at least eight correct genes in each gene set (Fig. 2b).
3.1.2 Specific driver gene set discovery.
First, we consider the situation of one cancer specific driver
gene sets. In sd3, SpeMDP can correctly detect the em-
bedded gene sets for K =2 to 10 (Fig. 2c). The results
on sd4 demonstrate that when the gene set is exclusive
in kind 1 (kind 2) set but not in kind 2 (kind 1) set, or
one is exclusive and the other takes background mutations,
SpeMDP can successfully identify it (Fig. 2d). In the first
case, the gene set is approximately exclusive in both kinds 1
and 2 sets which corresponds to a common driver pathway,
so SpeMDP cannot find it. In sd5, the mutation rates in kind
1 and kind 2 sets simultaneously get smaller and smaller,
so the mutation coverage will get small (so does the weight
W ) in kind 1 set along with i gets large (1 ≤ i ≤ I, I = 9),
and more exclusive mutation in kind 2 dataset will become
possible. Therefore, the performance to detect the embedded
gene set will decrease when i gets large (Fig. 2e). We further
validate this on sd6. The mutation rate of sd6 in kind 2
dataset gets larger and that in kind 1 set gets smaller along
with i becomes large (1 ≤ i ≤ I, I = 9). In this case,
we successfully identify all the embedded gene sets except
the one corresponding to i = 2 (Fig. 2f). Lastly, the result
on sd7 indicates that SpeMDP is also effective to identify
specific gene sets for multiple cancer types (Fig. 2g), where
the dataset is simulated in a similar way to that of sd6.
5Fig. 2. The results of simulation study. Accuracy of the common driver gene set discovery: (a) for K =2 to 10 with a constant mutation rate and (b)
for fixed K = 9 in which the embedded nine gene sets (I = 9) have decreasing mutation rates. (c) Accuracy of the specific driver gene set discovery
for K =2 to 10 with a constant mutation rate. (d) Illustration of the situation for specific driver gene set discovery: (1) two kinds of exclusive gene
sets corresponding to a common driver pathway, so it cannot be found; (2) exclusive (red) versus nonexclusive (brown) gene sets can be found; (3)
exclusive (red) versus random (brown) gene sets can be found. Numbers of correctly identified specific driver gene sets for ten runs with K = 6
and I = 9: (e) both kinds of gene sets have decreasing mutation rates and (f) one has increasing and the other has decreasing mutation rates. (g)
Numbers of correctly identified specific driver gene sets for ten runs about multiple cancer types with K = 6 and I = 9.
3.1.3 Individual driver gene set discovery approaches can-
not detect common and specific driver gene sets well.
For sd8, we first use the BLP model in MDPFinder [19]
to identify individual driver gene sets in each Ar which
contains seven embedded submatrices, and we get the ones
marked by ellipses in Fig. 3. Then we apply ComMDP and
SpeMDP to identify the common and specific driver gene
sets among all the Ars, and we obtain those marked by the
rectangle and dotted rectangles, respectively. Note that the
detected individual and common driver gene sets do not
have any overlap. Moreover, the detected individual driver
pathways in the second and third sets (A2 and A3) are not
specific (Fig. 3).
3.2 Applications to biological data
We investigate common driver gene sets among all the pair
mutation data of the 11 cancer types with K = 2 to 10. We
summarize all the significant driver gene sets with both in-
dividual and overall significance less than 0.05 (Suppl. Table
S1). The mutation rates of TP53 in LUSC and OV are very
high (164/182 and 405/445, respectively). We distinguish
this situations with or without TP53 when relating to these
two cancer types.
Common mutated driver gene sets among two or multiple
cancer types
Previous studies indicate that BRCA and OV have sim-
ilar phenotypes to some extent. Interestingly, we indeed
obtain significant common driver gene sets between them
by ComMDP for K = 7 to 10 (Table 1), and reveal 10 genes
TP53, PIK3CA, MAP3K1, MAP2K4, PIK3R1, LPA, KRAS,
ERBB2, FGFR2, TNXB in total. These genes are enriched
in several signaling pathways relating to apoptosis, ErbB
signaling pathway, PI3K-Akt signaling pathway, MAPK
signaling pathway, etc. Based on known KEGG pathway
knowledge (Fig. 4A), we propose a common mutated path-
way model for cancer initiation and progression in both
BRCA and OV (Fig. 4B). We show the heat map of the
alterations of the gene set forK = 10 (Suppl. Figure S1) and
see that TP53 has a very high mutation rate in OV (as stated
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Fig. 3. ComMDP and SpeMDP can exactly identify the embedded common driver gene sets (rectangle) and specific driver gene sets (dotted
rectangles), respectively. The BLP of MDPFinder [19] can identify the individual driver gene sets in each dataset (ellipses).
TABLE 1
Significant common driver gene sets between BRCA and OV identified by BLP
K Common pathways p1 p2 p
7 TP53, PIK3CA, MAP3K1, MAP2K4, PIK3R1, LPA, KRAS 0 0.003 0
8 TP53, PIK3CA, MAP3K1, MAP2K4, PIK3R1, LPA, KRAS, ERBB2 0 0.004 0
9 TP53, PIK3CA, MAP3K1, MAP2K4, PIK3R1, LPA, KRAS, ERBB2, FGFR2 0 0 0
10 TP53, PIK3CA, MAP3K1, MAP2K4, PIK3R1, LPA, KRAS, ERBB2, FGFR2, TNXB 0 0 0
p1 and p2 denote the p-values of the common gene sets in BRCA and OV, respectively. p represents the overall significance.
above). The mutation rates of other nine genes are very low.
It implies that TP53 mutation plays a dominant role in this
pathway in OV, indicating that the common driver pathway
exploration helps to identify driver ones with low mutation
frequency (Fig. 4).
We also employ BLP [19] to identify individual driver
gene sets in BRCA and OV (Table 2), respectively. For each
K in Table 2, there is only one common gene TP53 between
the identified gene sets for these two cancers. For other
genes in the common gene sets in Table 1, PIK3CA, MAP3K1,
MAP2K4 and PIK3R1 only appear in the gene sets of BRCA,
and KRAS, FGFR2 and LPA appear only in those of OV
(Table 2). Thus, only a local path of the common mutated
pathways (Fig. 4B) can be found by BLP for each of these
two cancers (Fig. 4C).
ComMDP has distinct advantages over both the gene-
centric frequency-based approaches and the individual
driver gene set based approaches. First, in the identified
common gene sets (Table 1), some genes have very low
mutation frequency. For example, TNXB, LPA and FGFR2 all
have less than five mutations in 466 BRCA samples and 445
OV samples, respectively. With such low frequency, these
genes cannot be discovered by the gene-centric frequency-
based approaches. But all the three genes have important
biological functions (Fig. 4B) and are closely related to the
carcinogenesis of BRCA and OV [37], [38], [39], [40]. For
instance, Hu et al. validated TNXB as a promising biomarker
for early metastasis of breast cancer [37]; Kim et al. demon-
strated TNXB might be helpful to predict the prognosis
of patients with stage III serous ovarian cancer through
differential expression analysis [38]; LPA and its receptors
play an important role in mediating malignant behaviors in
various cancers and recent studies [39], [41] suggested they
could be potential diagnostic biomarkers for BRCA and OV,
respectively; FGFR2 were suggested as candidate targets for
therapeutics in clinical trial for BRCA and OV [40], [42].
Second, some of the ten important common genes (Table
1) cannot be identified by the driver gene set identification
approaches for individual cancer type (Table 2). Especially,
TNXB and ERBB2 are not identified for any cancer by BLP.
Actually, ERBB2 is a well-known cancer gene, and it plays
a crucial role for certain subtypes of BRCA and OV patients
[43], [44]. Third, it is important to note that the individual
cancer type approach can only discover a small part of the
common gene set for each cancer type (Fig. 4), whereas
ComMDP can integrate information from different cancers
and imply a more biologically reasonable common driver
pathway.
Importantly, identifying all the significant common
driver gene sets of BRCA with certain cancer types will
help to understand various aspects of BRCA carcinogenesis.
Besides OV, other cancer types include BLCA, COADREAD,
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Fig. 4. (A) Known KEGG pathway knowledge in cancer. (B) A common mutated pathway model for BRCA and OV initiation and progression. It is
inferred based on the identified common gene sets and their participant pathway knowledge. The gene AKT1 relating to LPA with the PI3K-Akt
signaling pathway does not appear in the identified common gene sets. (C) Only local parts of the common mutated pathway in (B) can be found
by the individual cancer type approach BLP: (a) BRCA (up for 2 ≤ K ≤ 6, below for 7 ≤ K ≤ 10), (b) OV.
TABLE 2
Significant individual driver gene sets in BRCA and OV
K Driver pathway in BRCA Driver pathway in OV
2 TP53, PIK3CA TP53, KRAS
3 TP53, PIK3CA, GATA3 TP53, KRAS, IDI2
4 TP53, PIK3CA, GATA3, CDH1 TP53, KRAS, FGFR2, PIGV
5 TP53, PIK3CA, GATA3, CDH1, CTCF TP53, KRAS, IDI2, PIGV, BRAF
6 TP53, PIK3CA, GATA3, CDH1, CTCF, MACROD2 TP53, KRAS, IDI2, BRAF, LPA, EGFR
7 TP53, GATA3, CDH1, MACROD2, AKT1, MAP3K1, MAP2K4 TP53, KRAS, IDI2, BRAF, PIGV, EGFR, C4orf45
8 TP53, GATA3, CDH1, MACROD2, AKT1, MAP3K1, MAP2K4, PIK3R1 TP53, KRAS, FGFR2, C4orf45, EPHA3, PPID, ETFDH, FNIP2
9 TP53, GATA3, CDH1, MACROD2, AKT1, MAP3K1, MAP2K4, PIK3R1, TP53, KRAS, FGFR2, PIGV, EGFR, C4orf45, EPHA3, PPID,
POLD4 FNIP2
10 TP53, GATA3, CDH1, MACROD2, AKT1, MAP3K1, MAP2K4, PIK3R1, TP53, KRAS, IDI2, BRAF, LPA, C4orf45, EPHA3,PPID,
POLD4, ARID1A ETFDH, FNIP2
Here the p-values are all less than 0.0001.
GBM, HNSC, KIRC, LUAD and UCEC (Suppl. Table S1).
In total, we discover 38 different genes in all the eight
significant gene sets (Suppl. Figure S2). These genes are
involved in many important signaling pathways (Suppl.
Figure S3) and relate to diverse cancers (such as prostate
cancer, endometrial cancer, pancreatic cancer, lung cancer,
glioma, colorectal cancer, etc) (searched by DAVID [45]).
It is known that cancer is a very complex disease. We
integrate prior pathway knowledge and all the common
driver gene sets of BRCA with the eight cancer types to
explore more details about BRCA carcinogenesis (Fig. 5).
Compared to Fig. 4, we find some new paths and more
genes involving in the important hallmarks of cancer in
Fig. 5, such as [IFNA6–cytokineR/JAK–PI3K-Akt signaling
pathway–TP53–Fas–CASP8] leading to apoptosis, [ARID1A–
NF1–KRAS–MAPK signaling pathway] leading to prolifera-
tion, [GATA3–MAPK14] leading to cell survival, etc.
We note that, based on the common driver gene sets
of BRCA with multiple cancer types, we can get distinct
new discoveries versus previous work. For example, the
authors in [28] identified 127 significantly mutated genes
(SMGs) from diverse signaling and enzymatic processes,
and calculated the most frequently mutated genes in the
pan-cancer cohort for each cancer type. Especially, for
8Fig. 5. Hypothetical driver pathways for BRCA carcinogenesis and progression. It is inferred based on the common driver gene sets between BRCA
and other eight cancer types. The dotted arrows denote indirect effects, and a line represent a known interaction between them or co-occurrence
in a known signaling pathway. The ComMDP discovered genes are in red.
BRCA they obtained eight genes (TP53, PIK3CA, MAP3K1,
MAP2K4, GATA3, AKT1, CDH1, CBFB), seven of which
belong to our 38 genes except CBFB. On one hand, we
find more genes involved in the cellular processes that the
above eight genes relating to: transcription factor/regulator
(CTCF), genome integrity (ATM, BRCA2), MAPK signaling
(KRAS, NF1), PI(3)K signaling (PTEN, PIK3R1). On the other
hand, we detect several genes involved in other important
biological processes in cancer: histone modifier (ARID1A,
PBRM1, KDM6A), RTK signaling (FGFR2, FGFR3), cell cycle
(CDKN1B). This indicates that these biological processes
may also contribute to the carcinogenesis of BRCA. More
importantly, we identify some other genes that are not
included in the 127 selected genes in [28], but they play
also crucial roles, such as CASP8, IFNA6, ERBB2, TNXB,
NOTCH2 (Suppl. Figure S3). For example, CASP8 is in-
volved in the programmed cell death induced by Fas and
various apoptotic stimuli, and there are many studies re-
lating to its biological functions [46], [47], [48]; NOTCH2
plays a role in a variety of developmental processes by
controlling cell fate decisions, and has close relationship
with BRCA progression [49], [50]; IFNA6 belongs to the
family of interferon, although it has not been well studied,
this kind of immune-associated genes may be worth paying
great attention for immunotherapy of cancers [51].
Note that BLCA has common significant driver gene
sets with all the other 10 cancer types (Suppl. Table S1).
For BRCA stated above, some genes frequently appear in
many common gene sets (Suppl. Figure S2). But for BLCA,
the common gene sets are not necessarily the same, such
as those with BRCA (Suppl. Table S2), COADREAD (Suppl.
Table S3), GBM (Suppl. Table S4) and LUSC (Suppl. Table
S5). For example, we identify two different sets of genes
for BRCA and COADREAD, whereas their functional an-
notations are quite similar (Suppl. Figure S4). All these are
closely related to cancer generation and progression.
Furthermore, we also investigate the common mutated
driver gene sets among multiple cancer types. For example,
we find that BRCA, OV, LUAD and GBM have common
significant gene sets withK = 4 to 10 (Table 3), which relate
to the mutations of genes TP53, PIK3CA, KRAS, MAP3K1,
EP300, PIK3R1, TNXB, KDM6A, LPA and deletion of gene
IFNA6. As an example, we show the heat map of the
alterations of the gene sets in these four cancer types for
K = 4 (Fig. 6). These gene alterations are approximately
mutually exclusive in all the four cancer types. Compared
to the situation of only considering BRCA and OV (Table 1),
it covers three new genes. Besides IFNA6 stated above, two
others are EP300 and KDM6A. EP300 interacting with TP53
is a transcriptional coactivator to mediate many transcrip-
tional events including DNA repair [52]. It also functions
as a histone acetyltransferase to regulate transcription via
chromatin remodeling. Gene KDM6A is associated with
chromatin organization and transcriptional misregulation in
cancer [53]. Indeed, this investigation can help one to reveal
common characteristics among diverse cancers.
Mutated driver gene sets specific to one cancer or multiple
9TABLE 3
Significant common driver gene sets among BRCA, OV, LUAD and GBM
K Common pathway p1 p2 p3 p4 p
4 TP53, IFNA6, PIK3CA, KRAS 0.0010 0.0040 0.0020 0 0
5 TP53, IFNA6, PIK3CA, KRAS, MAP3K1 0 0.0020 0.0040 0 0
6 TP53, IFNA6, PIK3CA, KRAS, MAP3K1, EP300 0 0.0080 0.0040 0 0
7 TP53, IFNA6, PIK3CA, KRAS, MAP3K1, EP300, PIK3R1 0 0.0040 0 0 0
8 TP53, IFNA6, PIK3CA, KRAS, MAP3K1, EP300, PIK3R1, TNXB 0 0.0020 0.0010 0 0
9 TP53, IFNA6, PIK3CA, KRAS, MAP3K1, EP300, PIK3R1, TNXB, KDM6A 0 0.0040 0.0020 0 0
10 TP53, IFNA6, PIK3CA, KRAS, MAP3K1, EP300, PIK3R1, TNXB, KDM6A, LPA 0 0.0010 0.0080 0 0
p1, p2, p3 and p4 denote the p-values of the common gene sets in BRCA, OV, LUAD and GBM, respectively. p represents the
overall significance.
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Fig. 6. The heat map of the alterations in the common driver gene set
(TP53, PIK3CA, IFNA6, KRAS) among the four cancer types including
BRCA, OV, LUAD and GBM.
cancer types
We apply SpeMDP to the mutation data without com-
mon driver genes and identify several significant BRCA
specific driver gene sets relative to OV with K = 3, 4,
9, 10 (Table 4). These gene sets relate to the mutations of
GATA3, CDH1, AKT1, CTCF and amplifications of ERBB2,
WHSC1L1, CCND1, PLK1, RFPL4A, DDAH1, many of which
have been suggested to be closely related with breast cancer
initiation and progression by a number of studies [54], [55],
[56], [57]. For example, GATA3 plays a specific role in the
differentiation of breast luminal epithelial cells, and has
particular diagnostic utility in the setting of triple-negative
breast carcinomas [58]; the tumor suppressor CDH1 has
been shown to be a potential drug target in breast cancer
[54]; and epigenetic silencing of HOXA10 by CTCF in breast
cancer cells is related to tumorigenesis [55]. Similarly, we
also identify significant OV specific driver gene sets relative
to BRCA with K = 2 to 10 (Table 4), and significant BRCA
and OV specific driver pathways relative to the liquid cancer
LAML with K = 9, 10 (Suppl. Table S6).
The liquid cancer LAML has significant common or specific
driver gene sets compared to solid cancer types
LAML is the only liquid cancer in the current study. In-
terestingly, it has some common driver gene sets with solid
cancers. Specifically, by using ComMDP we identify LAML
has a significant common driver gene set with COADREAD,
GBM and BLCA for K = 5, which includes deletion of
IFNA6, and mutations of TP53, IDH1, WT1, SDK1.
More importantly, LAML is expected to have some
specific mutation patterns. We investigate LAML specific
driver pathways relative to other 10 solid cancers, and
discover significant driver gene sets with K = 2 to 10
except K = 5 (Table 5). These gene alterations include
mutations of FLT3, IDH2, NRAS, IDH1, RUNX1, NPM1,
TET2, KIT, amplifications of MLL, IGSF5 and deletions of
TP53, GNAQ. We show the heat map of the alterations of
the gene sets in all the 11 cancer types for K = 10 (Fig.
7) and see that the alterations display significant mutual
exclusivity in LAML, but not in other ten cancer types. Most
of these identified genes have been previously reported
to be related to LAML [59]. For example, eight genes of
them are involved with six functional categories associated
with LAML carcinogenesis (Fig. 8). Many large-scale studies
have confirmed that FLT3 can activate mutations in LAML
occurrence and disease progression and thus plays an im-
portant role in the pathogenesis of LAML [59], [60]; NPM1
is thought to be involved in several processes including
centrosome duplication, cell proliferation and regulation of
the ARF/TP53 pathway and its mutations are associated
with LAML supported by various studies [61], [62], [63];
KIT confers unfavorable prognosis for LAML patients [59].
Moreover, we can predict the potential implication of
GNAQ with LAML based on its appearance in the LAML
specific driver gene set even with very low mutation fre-
quency in LAML (2/164). GNAQ has been considered as one
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TABLE 4
BRCA and OV specific mutated driver gene sets relative to each other
Type K Specific pathway p q P
BRCA/OV
3 ERBB2, GATA3, CDH1 0.0110 1 0.0100
4 ERBB2, GATA3, CDH1, WHSC1L1 0.0360 0.9510 0.0300
9 ERBB2, GATA3, CDH1, WHSC1L1, CCND1, AKT1, CTCF, PLK1, RFPL4A 0.0410 0.7810 0.0420
10 ERBB2, GATA3, CDH1, WHSC1L1, CCND1, AKT1, CTCF, PLK1, RFPL4A, DDAH1 0.0160 0.7550 0.0280
OV/BRCA
2 BRCA1, BRCA2 0 0.6000 0
3 BRCA1, BRCA2, CACNA1A 0 0.6570 0
4 BRCA1, BRCA2, CACNA1A, WT1 1.0000e-03 0.6770 0
5 BRCA1, BRCA2, CACNA1A, CASC1, GUSBP3 0 1 0
6 BRCA1, BRCA2, CACNA1A, CASC1, GUSBP3, HUS1B 0 1 0
7 BRCA1, BRCA2, WT1, ADPRHL2, METTL17, DNM2, COX4I2 0 0.9970 0
8 BRCA1, BRCA2, WT1, ADPRHL2, METTL17, DNM2, COX4I2, SRP19 0 1 0
9 BRCA1, BRCA2, WT1, ADPRHL2, METTL17, DNM2, COX4I2, SRP19, PARP8 0 1 0
10 BRCA1, BRCA2, WT1, ADPRHL2, METTL17, DNM2, COX4I2, SRP19, PARP8, PRPS2 0 1 0
p and q denote the p-values of the gene set in BRCA relative to OV (BRCA/OV) or vice versa (OV/BRCA), respectively. P represents the overall
significance. Here the identified gene set is significant means that p and P are both less than 0.05, but q is larger than 0.05.
TABLE 5
LAML specific mutated driver gene sets relative to BRCA, HNSC, KIRC, LUSC, BLCA, GBM, LUAD, COADREAD, OV and UCEC
K Specific pathway p q1, · · · , q10 P
2 FLT3, IDH2 0.0150 1.0000, 1.0000, 1.0000, 1.0000, 1.0000, 0.0170
1.0000, 0.9520, 0.9890, 1.0000, 1.0000
3 FLT3, IDH2, NRAS < 0.0001 1.0000, 1.0000, 1.0000, 1.0000, 1.0000, 0.0010
1.0000, 0.9220, 0.7220, 0.9960, 0.8160
4 FLT3, IDH2, 0.0020 1.0000, 1.0000, 1.0000, 1.0000, 0.9480, 0.0020
NRAS, IDH1 0.9340, 0.8970, 0.5450, 0.9960, 0.8450
6 FLT3, MLL, IGSF5, 0.0180 0.5110, 1.0000, 1.0000, 1.0000, 1.0000, 0.0140
RUNX1, NPM1, TP53 1.0000, 0.9920, 0.9830, 0.9840, 0.9640
7 FLT3, IDH2, IGSF5, 0.0430 0.4720, 0.9940, 0.9930, 1.0000, 0.9630, 0.0240
RUNX1, NPM1, TP53, TET2 1.0000, 0.9930, 0.9930, 0.9800, 0.9410
8 FLT3, IDH2, IGSF5, MLL, 0.0050 0.5020, 0.9950, 1.0000, 1.0000, 1.0000, 0.0050
RUNX1, NPM1, TP53, KIT 1.0000, 0.9630, 0.8860, 0.9640, 0.9870
9 FLT3, IDH2, IGSF5, MLL, 0.0130 0.4890, 0.9900, 0.9960, 1.0000, 0.9710, 0.0050
RUNX1, NPM1, TP53, KIT, TET2 1.0000, 0.9650, 1.0000, 0.9680, 0.9950
10 FLT3, IDH2, IGSF5, MLL, GNAQ, 0.0090 0.3820, 0.9780, 0.9980, 1.0000, 0.9750, 0.0030
RUNX1, NPM1, TP53, KIT, TET2 1.0000, 0.9790, 1.0000, 0.9740, 0.9880
p, q1, · · · , q10 denote the p-values of the gene set in LAML, BRCA, HNSC, KIRC, LUSC, BLCA, GBM, LUAD, COADREAD, OV
and UCEC, respectively. P represents the overall significance. For each K, p and P are less than 0.05, but q1, · · · , q10 are all larger
than 0.05.
of uveal melanoma driver genes [64], and a prognostic factor
for mucosal melanoma [65]. Another study [66] indicates
that variations of GNAQ tend to occur in childhood LAML
patients. On the other hand, mutational-driven comparison
with other cancer types showed that uveal melanoma is
very similar to pediatric cancers, characterized by very few
somatic insults and, possibly, important epigenetic changes
[64]. Thus, we suggest that GNAQ might be a candidate
driver gene for childhood LAML patients and its function
in LAML carcinogenesis and progression worth further
exploration.
4 DISCUSSION
In this study, we develop ComMDP and SpeMDP to iden-
tify cancer common and specific mutated driver gene sets
among two or multiple cancer types, respectively. We first
apply them to a set of simulated data with diverse mutation
rates and pathway sizes to demonstrate their effectiveness.
We further apply them to real biological data from TCGA,
and obtain a set of cancer common and specific gene sets
which are involved in several key biological processes or
signaling pathways. This suggests that the identified com-
mon or specific driver gene sets may play crucial roles and
worth to be further explored.
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Fig. 8. Specific driver pathways or biological processes of LAML relative to the 10 solid cancer types. (a) Mutations in FLT3 confer a proliferative
advantage through the RAS-RAF, JAK-STAT, and PI3K-AKT signaling pathways. (b) Mutations in NPM1 result in the aberrant cytoplasmic
localization of NPM1 and NPM1-interacting proteins. (c) Deletions of tumor suppressor genes, such as TP53, lead to transcriptional deregulation
and impaired degradation through MDM2 and PTEN. (d) DNMT3A and TET2 mutations, as well as IDH1 and IDH2 mutations, can lead to the
deregulation of DNA methylation. (e) Mutations in myeloid transcription factors such as RUNX1 and transcription factor fusions by chromosomal
rearrangements lead to transcriptional deregulation and impaired hematopoietic differentiation. (f) Mutations of genes involved in the epigenetic
homeostasis of cells, such as mutations of ASXL1 and EZH2, lead to deregulation of chromatin modification as well as MLL-MLLT3 gene fusion,
which can impair other methyltransferases. Note: the genes in purple represent they appear in the identified specific driver gene sets. (Referring to
[59], [67])
Applications of ComMDP and SpeMDP to real data
show their advantages over both gene-centric frequency-
based approaches and individual driver gene set based
approaches. For example, we identified TNXB, LPA, FGFR2,
CASP8, NOTCH2 for BRCA, all of which are mutated with
very low frequency (less than fivemutations in 466 patients),
but have critical biological functions in carcinogenesis of
BRCA. All these genes cannot be discovered by the gene-
centric frequency-based approaches [28]. We also find that
some of the identified important common genes (Table 1)
cannot be detected by the driver gene set identification
approaches for individual cancer types [19]. Moreover, the
individual cancer type approaches can only discover a small
part of the common pathway for each cancer type (Fig. 4),
whereas ComMDP can integrate information from different
cancers and give a more biologically reasonable common
driver pathway. Furthermore, in the specific driver gene
sets of LAML relative to solid cancer types by SpeMDP,
GNAQ (with only two mutations in 164 LAML patients) has
showed potential implication with LAML carcinogenesis
and progression, but it cannot be detected by gene-centric
approaches.
We obtain the common driver gene sets of all pairs of
the 11 cancer types with K = 2 to 10 (Suppl. Table S1), and
note that the significance of common driver gene sets has
no transitivity. For example, there are significant common
driver gene sets between LAML and COADREAD as well as
LAML and LUAD for K = 3 to 10 (Suppl. Table S7 and S8).
But there are no significant ones between COADREAD and
LUAD for K = 2 to 10. In contrast, there are no significant
common gene sets between GBM and HNSC as well as
HNSC and OV for K = 2 to 10, but there are significant
ones between GBM and OV for K = 3 to 10 (Suppl. Table
S9).
In this study, to identify common driver gene sets,
we first select the genes which have mutations in all the
examined cancer types for further analysis. In fact, this
model can be generalized to include the genes which have
no mutations in some of the considered cancer types. We
may add some constrains to ensure that the number of
non-mutation cancer types is not more than a preassigned
number for any considered gene. Moreover, it can also
be used to investigate the commonalities and specificities
among different subtypes within a certain cancer. We expect
that our methods can provide crucial information for un-
derstanding the molecular mechanism of cancer generation
and progression.
5 AVAILABILITY
The methods are implemented in the MATLAB code and are
available upon request.
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Fig. 7. The heat map of the alterations in the LAML specific driver gene
set (FLT3, IDH2, IGSF5, MLL, RUNX1, NPM1, TP53, KIT, TET2, GNAQ)
relative to other ten cancer types including BLCA, BRCA, COADREAD,
GBM, HNSC, KIRC, LUAD, LUSC, OV and UCEC.
